Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.
Zeina Beidas, Anya Ragnhildstveit, Adam Blackman, Thomas Anderson, Emily C. Fewster, Omer A. Syed, Valentyne Sobolenko, Ismail Kaan Kanca, Tatiana Son, Norman A. S. Farb, Rotem Petranker
BJPsych Open May 13, 2026 DOI: 10.1192/bjo.2026.12000 (opens in new tab) via PubMed Central
Summary
AI-generated from the abstractThis is a correction notice for a previously published study protocol. The original protocol describes a phase II double-blind placebo-controlled randomised partial crossover trial investigating microdosing psilocybin for major depressive disorder. No new findings or data are presented.
Study at a glance
| Characteristics | Corrigendum Randomized Placebo-controlled Double-blind Peer reviewed |
|---|---|
| Population | Major depressive disorder |
| Key finding | This is a corrigendum to a study protocol for microdosing psilocybin for MDD; no results. |
Abstract
Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial - CORRIGENDUM.